A study published in the October Journal of Drugs in Dermatology is making news on two dermatology news sites. HCP Live and Healio have both written about, “Pharmacokinetic Profile, Safety, and Tolerability of Topical Berdazimer Gel, 10.3% in Patients With Molluscum Contagiosum.” The 12-week, open-label, multicenter trial evaluated the safety, tolerability and pharmacokinetic parameters of berdazimer gel, 10.3%, a novel, nitric oxide-releasing agent applied topically once daily. Patients were at least 6 months of age with at least 20 molluscum lesions. Investigators found the gel was well-tolerated with minimal systemic absorption. If FDA-approved, Berdazimer gel, 10.3% would be the first prescription medication indicated for molluscum contagiosum.
Healio also wrote about the October JDD study, “Phase 2 Trial of Topical Thykamine in Adults With Mild to Moderate Atopic Dermatitis,” by Charles Lynde, MD, and colleagues in Canada. The authors investigated whether a novel complex derived from organic baby spinach leaves would be safe and effective in treating atopic dermatitis. Researchers analyzed PUR 0110 cream at three dosages (0.05%, 0.1% and 0.25%) of concentrated and stabilized thylakoid membrane segments of various lengths. Compared to the vehicle, investigators found “PUR 0110 cream 0.1% demonstrated rapid improvement in signs and symptoms of atopic dermatitis with a favorable safety and tolerability profile.” The authors wrote that these findings support further investigation in phase 3 clinical trials.
Healio also highlighted an October JDD study, “Artificial Intelligence in Hair and Nail Disorders,” by Shishira R. Jartarkar, MD, and colleagues in India, Poland, Italy and Germany. The authors sought to provide an overview of currently available applications as well as potential applications. AI systems may be used to diagnose skin lesions on the scalp, count hair, and diagnose common hair disorders, such as dandruff, scalp folliculitis, hair loss and oily hair. Robotic hair restoration is another application of AI, as is the diagnosis of onychomycosis in nails. Current challenges are the paucity of images in various dermatologic diseases, and the present ability of AI to only recognize very few specific conditions. The authors wrote that clinicians should welcome AI as “it can be an excellent adjuvant to clinical practice, with rational use.”
The October JDD study, “Review of Tretinoin-Benzoyl Peroxide in The Treatment of Acne Vulgaris,” made news in Healio. Researchers conducted a literature review to assess the pharmacokinetics, efficacy and safety of recently approved Tret-BPO. They found Tret-BPO is a safe and effective novel therapy for acne vulgaris, although the efficacy is “not well-defined compared with other acne treatments.” The authors believe the combination of medications will aid in medication compliance as it reduces the complexity of treatment.
